
Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries
Key Takeaways
- Formosa and Cipla's agreement grants Cipla exclusive marketing rights for APP13007 in 11 countries, enhancing Cipla's ophthalmology portfolio.
- APP13007, approved by the FDA in March 2024, provides a twice-daily dosing regimen for post-operative ocular inflammation and pain.
The recent agreement with Cipla adds to the list of partnerships Formosa has formed for APP13007.
Formosa Pharmaceuticals and Cipla Limited have entered into an exclusive licensing agreement for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007) for post-operative inflammation and pain following ocular surgery.
Under the terms of the agreement, Cipla has exclusive rights to market APP13007 across 11 countries: India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, and Colombia.1
APP13007 was
Erick Co, president and CEO of Formosa Pharmaceuticals, and Achin Gupta, global chief operating officer of Cipla, both commented on the recent partnership in a press release.
"Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected global pharmaceutical brand. We appreciate their recognition and desire to add APP13007 to their rich portfolio of innovative medicines and look forward to working together to provide our novel therapy to ocular surgery patients to their audience," said Co.
"The partnership with Formosa Pharmaceuticals marks a significant milestone for Cipla, as it is our first multi-regional licensing agreement in ophthalmology. It reinforces our commitment to bringing cutting-edge treatments to patients worldwide. With exclusive rights to market APP13007 across 11 countries, we are excited to expand access to this innovative therapy and strengthen our ophthalmology portfolio,” said Gupta.
The strategic licensing agreement between Cipla and Formosa Pharmaceuticals includes upfront payments, royalty milestones, and additional value-driven considerations throughout its term.
References:
Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension. PRnewswire. Published March 18, 2025. Accessed March 20, 2025.
https://www.prnewswire.com/news-releases/cipla-and-formosa-sign-multi-regional-licensing-deal-for-clobetasol-suspension-302403405.html
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.